Compare POST & GRFS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | POST | GRFS |
|---|---|---|
| Founded | 1895 | 1940 |
| Country | United States | Spain |
| Employees | N/A | N/A |
| Industry | Packaged Foods | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Staples | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.1B | 6.2B |
| IPO Year | N/A | 2006 |
| Metric | POST | GRFS |
|---|---|---|
| Price | $98.22 | $8.71 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 6 | 2 |
| Target Price | ★ $125.33 | $10.15 |
| AVG Volume (30 Days) | ★ 700.2K | 485.7K |
| Earning Date | 02-05-2026 | 07-28-2022 |
| Dividend Yield | N/A | ★ 1.60% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 5.51 | 0.64 |
| Revenue | $8,158,100,000.00 | ★ $8,821,017,248.00 |
| Revenue This Year | $5.16 | $5.36 |
| Revenue Next Year | $0.36 | $5.15 |
| P/E Ratio | $18.03 | ★ $17.13 |
| Revenue Growth | 2.97 | ★ 7.31 |
| 52 Week Low | $95.07 | $6.19 |
| 52 Week High | $119.85 | $11.14 |
| Indicator | POST | GRFS |
|---|---|---|
| Relative Strength Index (RSI) | 46.45 | 40.06 |
| Support Level | $96.72 | $8.79 |
| Resistance Level | $101.09 | $9.40 |
| Average True Range (ATR) | 2.22 | 0.23 |
| MACD | 0.11 | -0.07 |
| Stochastic Oscillator | 42.81 | 3.19 |
Post Holdings Inc. is a consumer packaged goods holding company with products sold through grocery, club, and drug stores, mass merchandisers, foodservice, food ingredient, and eCommerce. It operates through four reportable segments: Post Consumer Brands, focused on North American ready-to-eat cereal and granola, pet food, and nut butters; Weetabix, focused on U.K. ready-to-eat cereal, muesli, and protein-based shakes; Foodservice, focused on egg and potato products; and Refrigerated Retail, focused on side dish, egg, cheese, and sausage products. Products are sold across channels, including retailers, wholesalers, convenience stores, pet supply retailers, drug store customers, military and national restaurant chains, with revenues largely generated in the U.S.
Grifols SA one of is global specialty plasma therapeutics companies developing, manufacturing and distributing a broad range of biological medicines based on plasma derived proteins. Plasma derivatives are proteins found in human plasma, which once isolated and purified, have therapeutic value. These protein-based therapies extend and enhance the lives of individuals who suffer from chronic and acute, often life-threatening, conditions, including primary and secondary immunological deficiencies, Chronic Inflammatory Demyelinating Polyneuropathy, immune-mediated ITP. Products and services are used to diagnose and treat patients with hemophilia, immune deficiencies, infectious diseases and a range of other medical conditions. Majority of revenue is from USA.